• McKinsey & Company predicts battery electric vehicles and plug-in hybrid electric vehicles will comprise over 55% of new vehicle production by 2030
• Hillcrest Energy is bringing to market novel inverter technology as EV manufacturers transition to next-generation technologies, including 800-volt platforms
• Hillcrest Energy has released white papers showing the value of its inverter tech to eliminate losses and reduce capacitor size and weight, while improving power, reliability, and product life

The last couple years have presented a spate of challenges to the electric vehicle (“EV”) industry. 2020-2022 has been marked by supply chain disruptions, spikes in wholesale costs, and rise in wsticker prices that earned the ire of some consumers despite government incentives supporting the transition away from fossil fuel-powered vehicles. A deeper dive reveals an industry in transition for the better, as new technology, such as next-gen inverters from Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F), improve efficiencies across the battery-powered spectrum. Spurred on by global mandates to curb emissions, the EV market is accelerating in the face of any obstacles. Pundits remain bullish on the future, including global management consulting firm McKinsey & Company predicting battery electric vehicles (“BEVs”) and plug-in hybrid electric vehicles (“PHEVs”) will comprise over 55% of new vehicle production by 2030 in North America, China, and Europe. If the European Union has anything to say about it, that estimate may be light considering the bloc recently upheld its ban of new internal combustion engine (“ICE”) vehicle sales after 2035. Hundreds of automakers are now focused on the EV space, leaving behind many conventional technologies in favor of those that make vehicles lighter, less expensive (in the long run) with greater range. Some are even experimenting with integrated solar body panels so the vehicle can harvest power non-stop. One trend is to ditch the 400-volt platform for an 800-volt system. 800-volt platforms require optimizations but are a value proposition by significantly improving efficiency while minimizing joule loss and weight (owing to less high voltage cabling requirements). Minimizing size is a popular theme in vehicle electrification, which squares with the products of Hillcrest as it develops a pipeline of transformative power conversion technologies and control system solutions for next-generation electric vehicles and electrical systems. Most recently, the British Columbia-based company has been highlighting a new soft-switching technology for improving power density through the reduction of capacitor and overall inverter size. Generally speaking, there are a bank of capacitors in an inverter for the purpose of allowing pulses of electrical current to happen at different times and frequencies. This action serves several purposes, including reducing the amount of peak-to-peak ripple voltage. Smaller capacitors mean smaller inverters, which translates to less weight without sacrificing performance. In fact, it can improve performance and lower costs. Industry-wide, extrapolating small changes in materials and battery capacity can translate to large reductions in supply chain demand. In August, Hillcrest released a technical white paper outlining the advantages of its novel Zero Voltage Switching inverter and how its soft-switching capabilities relate to capacitors within the power conversion system. The report details the benefits of operating electrical systems at higher switching frequencies as a means to substantially reduce capacitor size, and improve power and reliability, while extending component life. It followed a July report on how Hillcrest technology eliminates losses and improves motor efficiencies. Hillcrest says that it is on schedule to deliver commercial prototypes of its new inverter to interested parties, including multiple global tier 1 automotive suppliers and original equipment manufacturers (“OEMs”), by the fourth quarter. The company has overcome typical issues with developing new inverter technology, namely eliminating high-frequency ringing in the power modules. “Based on our ongoing conversations with potential customers, we believe our business model – largely based on a combination of unique, application-specific hardware and software designs and ongoing product royalties/fees – aligns perfectly with what the industry is looking for,” said Hillcrest CEO Don Currie in a statement. He added that the strategy is to retain ownership of its core intellectual property and de-risk via creating multiple revenue streams by choosing a select group of non-exclusive partners that could deploy the inverters throughout different markets and sectors. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technology
• The company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffness
• Although hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the condition have it under control
• A Harvard Health article notes that the remaining portion (47%) are not able to control the disease because they are discouraged by medications’ side effects
• Lexaria’s DehydraTECH-CBD may well be the solution such individuals seek, but for now, the company is following the regulatory pathway to eventual drug approval

Hypertension causes life-threatening conditions such as stroke, heart attacks, coronary artery disease, and heart failure. But even more concerning, the condition leads to death. In 2020, the U.S. Center for Disease Control (“CDC”) reported that high blood pressure claimed more than 670,000 lives in the U.S. (https://ibn.fm/TI3fx). Globally, hypertension claims an estimated 7.5 million lives annually, according to the World Health Organization (“WHO”) (https://ibn.fm/3yda2). Despite these devastating consequences and statistics, only about half (53%) of Americans living with high blood pressure have it under control, a problem that a Harvard Health article attributes to, among other common reasons, the fact that many stop taking their medication citing side effects (https://ibn.fm/ScKA6). As a result, scientists and researchers have continuously explored ways to increase the chances of success as regards having the condition under control. One such study, a clinical trial, employed “a new strategy where patients are started on a pill containing four medicines, each at a quarter of their usual doses. [The strategy] has been shown to be much more effective in getting blood pressure under control, compared to the common practice of monotherapy, where treatment commences with just one drug” (https://ibn.fm/CbeZQ). For researchers and scientists at Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, their quest takes a different approach that combines the effectiveness of the company’s proprietary DehydraTECH(TM) drug delivery technology and the emerging benefits of cannabidiol (“CBD”), one of which is the substance’s ability to slow down the heart rate and blood pressure, particularly in stressful situations (https://ibn.fm/uDCGb). In the latest tests, DehydraTECH-CBD has undergone human evaluations, yielding promising results. CBD lowers systolic blood pressure in isolation (https://ibn.fm/U9xBC). However, with the addition of DehydraTECH, its capability and performance are boosted even further (https://ibn.fm/FZDkU). This is chiefly because DehydraTECH increases CBD’s bioavailability, a term that refers to the percentage of a drug that enters the bloodstream and becomes available to the intended biological target. In its first human study, conducted in 2018 and involving 12 patients, Lexaria showed that DehydraTECH delivered 317% more CBD to the bloodstream 30 minutes after ingestion (https://ibn.fm/gNDcX). Since then, the company has undertaken a series of other human studies. 2021, in particular, saw the company complete three studies: HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3. The first study evidenced a rapid and sustained decrease in blood pressure, particularly systolic pressure. The second study showed that DehydraTECH-CBD caused a 23% average reduction in overnight blood pressure in addition to reducing arterial stiffness. The third revealed that the substance caused a 41% overall attenuation in pulmonary artery systolic pressure among male participants. Its fourth study, HYPER-H21-4, is its most comprehensive yet. With dosing having been completed in late July, Lexaria announced that no serious adverse events were reported. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorization,” Lexaria CEO Chris Bunka said of the HYPER-H21-4 study (https://ibn.fm/BHKt1). The company looks to leverage the results of the fourth study to file an Investigational New Drug (“IND”) application seeking the U.S. Food and Drug Administration (“FDA”)’s approval to begin registered clinical testing at Phase I level or higher. The study, Lexaria observes, is designed to boost the company’s probability of success with the application. And as analysis contained in an August 11 press release shows, the commencement of Phase I (or even higher) studies, as and when it happens, could portend good tidings for the company’s investors. According to a valuation guide authored by Bay Bridge Bio, the potential valuation of a company increases as a company’s clinical trials move from Phase I through Phase III. Accordingly, Lexaria’s valuation may trend upward with time (https://ibn.fm/7kBHk). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The UK has witnessed the fourth consecutive year of growth for independent artists and is on track for a fifth, exhibiting 28.9% penetration YTD in 2022
• Independent artists are not afforded the same support from the music industry with the option of maintaining control over their work
• Friendable’s Fan Pass Live artist platform is a 360-degree platform approach to music production, distribution, and marketing that keeps ownership in the artist’s hands

The music industry has traditionally been dominated by major record labels and their recording artists – but in 2021, the UK saw the fourth year of consecutive growth for independent artists, growing to just under 27% of the country’s music market share. This number was boosted by classic LP releases and 60 albums entering the Top 10 Official Albums Chart. The UK’s positive trend for indie artists continues into 2022 with 28.9% YTD, boosted by number one albums from The Wombats, Don Broco, Stereophonics, and rapper Central Cee (https://ibn.fm/YHGrw). Unlike mainstream record label artists, indie artists do not have the same support from the industry when producing, distributing, and marketing music – they must rely on third parties for help with this, which can result in a search for three or more separate entities to make these endeavors possible. One company is changing this dynamic for indie artists, making it possible for them to produce, distribute, and market their music on one platform. The platform – Fan Pass Live, the flagship offering from Friendable (OTC: FDBL), a mobile technology company and marketing company, accompanied by the company’s Artist Republik and FeaturedX offering, provides a 360-degree solution for indie artists who want to be in full control of their music production, distribution, and marketing efforts. The Fan Pass Live artist platform offering gives indie artists an advantage in today’s music industry, featuring:

• Music Distribution and Management
• Music Production Assistance
• Press Release and Instagram Promotion
• Digital Storefront Activation
• Artist Marketplace for Collaborations
• Merchandise, Logo, and Promotional Design Support
• Virtual Concert Booking and Ticketing Mobile Streaming Service
• Live Streaming Support
• Revenue from Fan Tips, Monthly Artist Contests, Merchandise, and Ticket Sales
• Access to Fan Data and Performance Analytics
• Monthly Artist Contests
• NFT Development and Metaverse Performances – coming soon

All of these options are available in one place – the first of its kind in the industry today, with affordable services provided by artists for artists. Through the Fan Pass Live artist platform, Friendable is making it possible for indie artists to be heard without the fees and contracts required by traditional record labels, with the support and stability of experts in the industry. The global independent artists and performing art companies’ market size is expected to continue growing, from $101.33 billion in 2021 to $163.14 billion in 2022, experiencing a CAGR of 61%. By 2026, the market is expected to reach $328.87 billion, growing at a CAGR of 19%. The growth is primarily due to companies rearranging operations and recovering from the impact of COVID-19, which had led to restrictions, including remote working, closures of commercial venues, and subsequent operational challenges (https://ibn.fm/gPKeD). With the advantage of offering indie artists various services on one localized platform, Friendable and the Fan Pass Live artist platform remove the guesswork artists go through when finding ways to get their music heard. The company is changing the dynamic of the music industry by providing a highly sought solution that enables indie artists to keep complete ownership of their music while also distributing and marketing it with the full support of the platform. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Power inverter technology critical to electric motor operation, converts energy from DC to AC power
• Inverter size and power density present design and mechanical challenges to EV manufacturers
• Hillcrest’s technology solves challenges with smaller, lighter inverter solutions that reduce weight, increase payload, decrease heat production, boost range
• Company recently released series of technical whitepapers that validate technology

Electrification technology continues to make strides; however, inverter size and power density continue to present design and mechanical challenges to manufacturers in the EV space. Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F), a clean technology company, addresses these challenges with conversion technologies and control systems solutions that reduce the size and weight of inverter designs with the potential to disrupt the electrification industry. “Capacitance for a typical EV traction inverter today is between 600 micro farads and 1 millifarad, while the commercial prototype design of the Hillcrest traction inverter contemplates one-fifth to one-tenth of the capacitance,” says Hillcrest CTO Ari Berger (https://ibn.fm/puF40). “Such a significant reduction in capacitor and inverter size and increase in power density, coupled with improved power quality and system reliability, has the potential to disrupt power inverter designs across the automotive space.” Capacitors work by allowing for pulses of electrical current to occur at different times and frequencies. These pulses act as an energy buffer while reducing the amount of peak-to-peak ripple voltage that can compromise the process. Capacitors are therefore critical to the function of the motor, however the bank of capacitors in the inverter contributes to the component’s size and weight, posing mechanical and design challenges for manufacturers. Enabling switching at higher frequencies with Hillcrest’s Zero Voltage Switching (“ZVS”) inverter technology can result in a significant increase in power density, partly due to the reduction in the size of capacitors needed and in turn reducing the overall size, weight and cost of an inverter. Hillcrest’s technology allows for smaller, lighter high-efficiency power inverter solutions that reduce overall weight, increase payload, decrease heat production, and boost the vehicle’s range capability. The company continues to validate this technology with a series of whitepapers that showcase the value of its technology from various technical and sub-system aspects (https://ibn.fm/iYA7l). Last month the company released a report that demonstrated the value of operating electrical systems at higher switching frequencies with the ability to eliminate losses. The most recent white paper explains how operating at higher switching frequencies can result in a significant reduction in the size of capacitors within the system, in addition to improving power output, quality, system reliability, and component life. Based in Vancouver, British Columbia, Hillcrest develops transformative power conversion technologies and control system solutions for next-generation electrical systems. As the world moves forward on the path toward electrical energy systems, the company is strongly positioned to provide disruptive technologies that unlock performance and efficiency across the entire electrification value chain. To download the latest technical white paper, visit https://HillcrestEnergy.tech/reports. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• GMGI acquired 80% stake in RKings social gaming platform that earned $32 million in revenue and $2.6 million in net income during fiscal 2021
• Permit application for Mexico approved others to follow as more governments legalize online gambling
• Online gambling revenues expected to reach $153.6 billion by 2030 at CAGR of 11.7 percent from 2022 to 2030

Golden Matrix Group (NASDAQ: GMGI), an iGaming leader based in Las Vegas, develops, and owns online gaming IP, turnkey online casino solutions, and configurable, scalable white-label gaming platforms for international gaming operators. The company’s extensive portfolio of proprietary technology has made it a leader in B2B solutions, evidenced by record-breaking revenues and non-stop profitable quarters (https://ibn.fm/423iI). Backed by its stellar financial track record, GMGI is moving into the B2C social gaming sector. The company recently purchased an 80% stake in UK-based RKingsCompetitions Ltd. in December 2021, with the rights to acquire the remaining 20%. RKings is a prize competition business based in Ireland and the United Kingdom that offers paid and free entrance routes for customers to win a range of consumer products ranging from automobiles to luxury vacations. “This significant upgrade to the RKings platform will accelerate the growth of our B2C businesses, offering added functionality and features and also allowing us to expand into new geographic regions and strengthen our global footprint,” said Golden Matrix CEO Brian Goodman (https://ibn.fm/wo1qp). “We believe the GMGI/RKings product offerings will be received enthusiastically by players in all regulated markets where we are licensed. At a time when global economic growth is being challenged, we are fortunate to have a scalable business model that has already demonstrated consistent profitability.” Online gambling is growing rapidly because of casino closings due to COVID-19 restrictions, new product offerings, and increased legalization throughout the world. Grandview research estimates revenues to reach $153.6 billion by 2030 at a CAGR of 11.7 percent from 2022 to 2030 (https://ibn.fm/fukGd). GMGI’s permit application for Mexico was recently approved, and others are expected to follow as the company continues to roll out its expansion strategy. “This a logical move for the company, as it opens up compelling opportunities in the Latin America (‘LATAM’) B2C market; and it begins the expansion of the RKings tournament platform to our first region outside of the UK and Ireland,” said Goodman (https://ibn.fm/Nsy7V). “We are confident that, in addition to casino games and sports book betting, RKings will be received enthusiastically, generate significant revenues, and boost our overall profitability.” Golden Matrix leads the iGaming industry with turnkey B2B iGaming and Esports solutions and plans to diversify revenues via entry into the B2C social gaming sector. The company’s gaming IP features tools for marketing, acquisition, retention, and monetization of users, and its platform can be accessed through both desktop and mobile applications. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• The recently passed Inflation Reduction Act of 2022 will extend the investment tax credit, providing residential solar users with a tax credit equivalent to 30% of the cost of equipment
• The tax credits will seek to incentivise the continued growth of the US solar energy sector
• Although new solar energy capacity accounted for half of the growth of electricity generation capability within the US in 1Q22, the nation’s cumulative solar energy capacity is sufficient to power a mere 18 million homes
• Through its revolutionary SmartGreen(TM) Home solution, GeoSolar Technologies will help household lower both, their carbon footprint as well as their utility bill outlay

The newly passed Inflation Reduction Act of 2022 has been hailed for its extensive remit, ranging from curbing inflation through a reduction of the United States fiscal deficit through to cutting prescription drug prices. However, one of the most impactful provisions within the bill is the long-term extension of the investment tax credit, a subsidy which has been instrumental in launching the US solar industry as we know it today. The bill calls for a 10-year extension of subsidies in the form of tax credits valued at 30% of the cost of the installed equipment, which will then step down to 26% in 2033 and 22% in 2034. Moreover, the tax credit also applies to residential adopters of solar technology; in effect, the 30% credit will retroactively apply to anyone who installed their system dating back to the beginning of 2022 – a welcome outcome for the likes of Colorado-based GeoSolar Technologies (“GST”), a climate technology company seeking to harness renewable energy sources to power and purify homes and automobiles without the use of fossil fuels. “With long-term incentives for clean energy deployment and manufacturing, the solar and storage industry is ready to create hundreds of thousands of new jobs and get to work building out the next era of American energy leadership. This is a crucial window of opportunity that we cannot miss, and now Congress must seal the deal and pass this legislation,” stated Abigail Ross Hopper, president of the Solar Energy Industries Association (https://ibn.fm/uEd7c). However, and despite the positive news-flow surrounding the US solar energy sector, adoption of solar power by American residential & commercial consumers remains woefully low. California is currently the only state which derives upwards of 20 percent of their electricity from solar power, sufficient to power 7.9 million homes (https://ibn.fm/LHVW1). Meanwhile, an astonishing 26 states develop less than 1 percent of their grid energy from solar sources. Despite its long-term economic benefits – solar power is more economical than conventional energy sources when amortised over the lifetime or the solar panel system (about 20 years), solar adoption has become inequitable, with a decided skew towards higher-income households. A key factor has been the elevated upfront cost of a residential solar power system, costing anywhere between $3,500 to $16,000, with the wide range a factor of the system being installed as well as the type of panels being utilized (https://ibn.fm/OrqDl). Additionally, potential cost savings are not straightforward to calculate. The solar energy generated by a residential system is oft quoted in terms of the theoretical electrical output potential in watts. However, the typical output realized for installed photovoltaic (“PV”) systems—known as the capacity factor—is between 15% and 30% of the theoretical output (https://ibn.fm/b80WB). The generated output then must be factored against the cost of energy being drawn from the local electricity grid. This can vary greatly, depending on whether a local utility charges customers a flat rate for electricity, regardless of the time of consumption or whether pricing varies at different rates throughout the day to mirror the actual cost of electricity production at different times. GeoSolar Technologies’ home energy solution has sought to adopt a multi-pronged approach towards electrifying homes using green energy sources. From solar panels on roofs through to geothermal heat pumps which take advantage of the warmth of the earth’s core and advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, the GeoSolar’s proprietary SmartGreen(TM) Home solution has been designed to dramatically increase the energy efficiency of a conventional household. Moreover, the technology voids the need for households to depend on conventional utilities or pay utility bills. In fact, a study carried out by the company found that a traditional utility-powered home would possess a carbon footprint of upwards of 8 tons of CO2/year whilst paying annual utility bills of $2,700; in contrast, a GeoSolar-powered home would result in a negligible carbon footprint whilst disbursing less than $100 per annum in utility bills (https://www.geosolarplus.org/geosolarplus). From just 0.34 GW in 2008, U.S. solar power capacity has grown to an estimated 97.2 gigawatts (“GW”) today, enough to power 18 million average American homes.  The growth has coincided with a significant reduction in solar component charges; since 2014, the average cost of solar PV panels alone has dropped by nearly 70% (https://ibn.fm/KcIfZ). Nonetheless, the potential for solar energy within the United States remains relatively untapped. For instance, PV panels on just 22,000 square miles of the nation’s total land area – about the size of Lake Michigan – could supply enough electricity to power the entire United States (https://ibn.fm/DZgJm). That paradigm has begun to shift now. In the first quarter of 2022, the United States installed 3.9 gigawatts of solar PV capacity, equivalent to 50 percent of all new electricity-generating capacity added within the United States over the three-month period. GeoSolar Technologies are now looking to further that trend, both in terms of reducing their clients’ carbon emissions whilst contributing to reducing their utility bill outlays. As Marilyn Lopez, Partner and Co-Founder of TAG Collective, a company currently overseeing GST’s company’s marketing efforts for its upcoming Reg A+ offering remarked on GeoSolar Technologies’ prowess and capabilities. “There may not be a company in the climate technology industry that is doing more in the battle against rising global temperatures.” For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”)
• So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancer
• It remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to patients and address a huge worldwide market

When CNS Pharmaceuticals (NASDAQ: CNSP) decided to go public in November 2019, its Chief Executive Officer (“CEO”), John Climaco, expressed his optimism about the next chapter in both the company’s operations and performance. Since its inception in 2017, he noted, the company had been working “under the radar and within its capital means,” and the Initial Public Offering (“IPO”) would offer an opportunity for it to scale up its operations (https://ibn.fm/NeVra). “This company has been built slowly and carefully, laser-focused on a single mission- trying to really move the needle in [glioblastoma] and brain cancers in general,” noted Mr. Climaco. “I think we’ve got all the pieces in place now,” he added. After the 2019 IPO the company’s management noted that the proceeds would fund its clinical trials and pre-clinical programs for other research and development activities and general corporate purposes. In addition, it would form the foundation for the company’s pivotal glioblastoma (“GBM”) study, which has since earned Fast Track Designation from the U.S. Food and Drug Administration (“FDA”). As a pre-clinical stage biotechnology company specializing in developing novel treatments for brain tumors, CNS has focused on its lead drug candidate, Berubicin, to potentially treat GBM. However, this candidate has also shown tremendous potential in treating other central nervous system malignancies, appearing to be the first anthracycline to cross the blood-brain barrier in the adult brain. Before the IPO, CNS estimated that over $25 million in private capital and grants were invested in Berubicin in what could be described as the company’s confidence in the product’s potential and what it could do should it receive FDA approval. The initial objective was to submit an Investigational New Drug (“IND”) application during the fourth quarter of 2020, with the commencement of Phase II clinical trial in the first quarter of 2021. CNS has since made significant headway, even receiving FDA Fast Track Designation, which now offers it an accelerated path to approval for Berubicin. “With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,” noted Mr. Climaco (https://ibn.fm/fO3fh). GBM’s median survival from initial diagnosis is less than 15 months, with a 2-year survival rate of 26-44%. Globally, it affects 5 out of every 100,000 people, making it the most common and devastating primary malignant brain tumor affecting adults. CNS hopes its research will offer a solution to the millions of people currently dealing with GBM globally. Given how much promise Berubicin has shown, its management is optimistic that with additional studies, it will get to offer a much-needed treatment option for the condition. “With the recent regulatory authority approvals received in Europe, we are currently on the cusp of opening clinical sites globally, including France, Italy, Spain, and Switzerland, to expand the scope and outreach to patients for this trial,” noted Sandra L. Silberman, the Chief Medical Officer (“CMO”) of CNS. “We remain dedicated to driving this study forward and ultimately hope to provide a much-needed option for treatment in GBM as a safe and effective therapy,” she added. CNS remains committed to pushing the envelope in terms of research and development of potential GBM treatment. Through this, it hopes to take advantage of the growing brain tumor therapeutics market, projected to hit $2.74 billion by 2023, posting a CAGR of 11% over the forecast period (2018-2023). But, more importantly, through its efforts, CNS looks to offer relief and a viable solution to millions of people globally who are dealing with GBM. Doing so will not only offer a unique solution unlike any currently in the market but also will create tremendous value for its shareholders as it pushes the GBM conversation forward. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• REZYFi Lending sees higher margin lending opportunities as well as significant market opportunity to provide the growing and underserved cannabis industry with financial services
• ResMac forecasts $285 million in retail loan origination in 2023 and foresees strong growth opportunities
• ResMac is on pace to originate $250 million in wholesale loan business in 2023, with its year-over-year credit facility increase expected to jump more than 300%
• The company’s management team has more than 40 years’ experience in the mortgage and lending industry
• REZYFi expects to operate nationwide by the end of 2022; it currently operates in 34 states

REZYFi is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects. Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year. REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry. Operations REZYFi Lending REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages. Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year. ResMac Inc. ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023. Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators. The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered. Corporate Strengths

• Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
• Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
• Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come. In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture. The National Association of Realtors(R) issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives. In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028. Management Team John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers. Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million. Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations. Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin
• These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin
• After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003

A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol use disorder (“AUD”) and major depressive disorder (“MDD”) (https://ibn.fm/5IPD1). In addition to reporting three million deaths annually attributed to alcohol use (5.3% of all deaths), the World Health Organization (“WHO”) states that the harmful use of alcohol is a causal factor in more than 200 diseases and injury conditions and that, overall, 5.1% of the global burden of disease and injury is attributable to alcohol (https://ibn.fm/ytu6c). These statistics make the JAMA-published study even more significant. The study, conducted by the Department of Psychiatry at New York University’s (“NYU”) Langone Center for Psychedelic Medicine, discovered that providing two doses of psilocybin and psychotherapy reduced heavy drinking by 83% within eight months. “In this double-blind, randomized clinical trial with 93 participants, the percentage of heavy drinking days during 32 weeks of follow-up was significantly lower in the psilocybin group than in the placebo group, containing the antihistamine diphenhydramine,” the article stated. By contrast, those who received the antihistamine placebo only reduced their drinking by 51%. All participants received up to 12 psychotherapy sessions before and after the psilocybin treatments. The study concluded that administering psilocybin in combination with psychotherapy “produced robust decreases in the percentage of heavy drinking days over and above those produced by active placebo and psychotherapy. These results provide support for further study of psilocybin-assisted treatment for Alcohol Use Disorder (‘AUD’).” These results align with the efforts and expectations of Cybin, which is creating Psychedelics to Therapeutics(TM). The company is making significant headway with its flagship deuterated psilocybin analog, CYB003. CYB003 has the potential to effectively treat AUD and MDD. The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a “may proceed” letter and Investigational New Drug Application (“IND”) clearance from the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human clinical trial evaluating CYB003 (https://ibn.fm/OQsmP). This milestone achievement marks the industry’s first-ever novel psilocybin analog to enter clinical development; the company has started recruiting patients and expects to provide an interim pharmacokinetic and safety readout later this year. “We are extremely pleased to advance CYB003 into clinical development so quickly,” said Cybin CEO Doug Drysdale. “Our team has worked diligently to achieve this major regulatory milestone, and we look forward to collaborating with Clinilabs, our drug development partner, to accelerate this program. This Phase 1/2a trial represents the first time that a psilocybin analog will be evaluated in humans for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering from mental health conditions.” For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Plant-based foods investment company Eat Well Investment Group Inc. is an innovative producer of food products designed to help nations respond to food security concerns and do so with healthful alternatives to established supply methods
• Eat Well recently announced the appointment of plant-based industry pioneer Bernhard Van Lengerich to the company’s advisory board
• Van Lengerich is experienced in senior leadership at companies such as General Mills, Beyond Meat, RJR Nabisco and Unilever, and he is the inventor or co-inventor on over 150 patents
• Eat Well Group’s 100 percent-owned subsidiary Sapientia is focused on innovating new plant-based snack foods for people and pets, while subsidiary Belle Pulses drives the company’s food security response with pea-based protein products
• Eat Well’s subsidiaries, which also includes baby food maker Amara, are poised to increase their distribution outlets during the coming months

The appointment of plant-based industry pioneer Bernhard Van Lengerich to the advisory board of foods investment company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) highlights the company’s drive to boost innovation in an industry with roots reaching back centuries even though it is still in its early stages, thanks to new consumer interest in economical alternatives to established food supply methods. Van Lengerich’s experience includes senior leadership positions at General Mills, Beyond Meat, Buhler, RJR Nabisco, Unilever, and the German Institute for Food Technology, and he the inventor or co-inventor on over 150 patents, according to a news release issued by the company. “We are honored to welcome Bernhard to Eat Well Group. His experience and track record in not only major plant-based foods companies, but global consumer products, is unparalleled, and even more importantly, his values align with our mission,” Eat Well Group CEO and Director Marc Aneed stated in the release (https://ibn.fm/ewVNU). “We look forward to working with him to assist management, help advise our portfolio companies, and review potential investments that have the ability to change our world for the better.” Eat Well Group’s food industry portfolio companies include 100 percent-owned subsidiary Sapientia, a developer of plant-based snacks tasked with providing revolutionary new options for health-conscious consumers. Sapientia’s first product, a white-labeled protein twist, launched in December and is being distributed through Federated Co-op stores in western Canada and the company expects to more than double the hundreds of stores the protein twist is available in through Q3. Sapientia’s proprietary foundation for the snack is its development of processing technology that allows the company to create a product with the textural attributes of a fried snack without using fried processing. And the snack maintains a high nutritional value. Sapientia’s research and development team has continued moving ahead in the meantime with plans for producing and distributing pet treats and new forms of “kid household” snacks bearing Sapientia’s signature approach to healthful foods. And the company is developing a direct store delivery (“DSD”) strategy for regional markets that it hopes to put in motion later this year (https://ibn.fm/HNtpa). Healthful snack foods is only one part of Eat Well Group’s sphere of operations. Its primary revenue driver has been its pea-based foods production through 100 percent-owned subsidiary Belle Pulses, which supplies international markets with protein alternatives to meat products. And Eat Well’s significant holdings in Amara Organic Foods gives it a competitive stake in the production of healthful foods for babies and young children. “Food security has become a major concern around the world. From severe weather to disrupted supply chains, and global conflicts, making our investment thesis more timely than ever. Real food, right now, is what the world needs, and that’s what Eat Well’s portfolio companies are supplying every week,” Aneed added. “We are incredibly excited for where we are headed and expect the management teams to continue ramping up well into the future.” For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF